To evaluate the anti-tumor activity of the nanoparticle-delivered therapeutic siRNA targeting BCL2 and BIRC5, the siRNAs were delivered to Ca9-22 cells by the nanoparticles as described in Section 3.3. The gene discussed is BCL2; the disease is neoplasm.